The Comparative Effectiveness and Safety of Second-line Therapy in Patients with Type 2 Diabetes

2 型糖尿病患者二线治疗的有效性和安全性比较

• 批准号: 10427202
• 负责人: Jung-Im Shin
• 金额: $ 15.1万
• 依托单位: JOHNS HOPKINS UNIVERSITY
• 依托单位国家: 美国
• 财政年份: 2019
• 资助国家: 美国
• 起止时间: 2019-07-01 至 2024-04-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/10427202
• 关键词: Address; Age; Agonist; Agreement; American; American College of Physicians; Amputation; Antidiabetic Drugs; Benefits and Risks; Blood Pressure; Body mass index; Cardiovascular Diseases; Caring; Characteristics; Chronic Kidney Failure; Clinical; Consensus; Creatinine; Decision Making; Diabetes Mellitus; Dipeptidyl Peptidases; Doctor of Philosophy; Educational Curriculum; Effectiveness; End stage renal failure; Endocrinologist; Epidemiology; Event; Five-Year Plans; Foundations; Fracture; GLP-I receptor; General Population; Glucose; Glycosylated hemoglobin A; Goals; Guidelines; Health; Health system; Healthcare; Heart failure; Hyperglycemia; Hypoglycemia; Incidence; Infection; Insulin; International; Israel; Knowledge; Lead; Measurement; Mediating; Mentored Research Scientist Development Award; Mentors; Mentorship; Metformin; Methods; Morbidity - disease rate; Non-Insulin-Dependent Diabetes Mellitus; Oral; Outcome; Participant; Patient-Focused Outcomes; Patients; Pattern; Persons; Pharmaceutical Preparations; Pharmacoepidemiology; Pharmacology; Public Health; Public Health Schools; Race; Recommendation; Renal function; Research; Research Proposals; Resource-limited setting; Risk; Risk Assessment; Robin bird; Safety; Scientist; Socioeconomic Status; Sodium; Subgroup; Sulfonylurea Compounds; Sweden; Therapeutic; Thiazolidinediones; Time; Training; Uncertainty; Weight Gain; World Health Organization; adverse event risk; cardiovascular disorder risk; career; clinical practice; cohort; comparative effectiveness; comparative safety; cost; diabetes management; experience; glycemic control; improved; individual patient; inhibitor; mortality; novel; novel therapeutics; obese patients; optimal treatments; programs; sex; side effect; skills

PROJECT SUMMARY/ABSTRACT Jung-Im Shin, MD, PhD, is an Assistant Scientist in the Department of Epidemiology at the Johns Hopkins Bloomberg School of Public Health. She seeks a K01 Mentored Research Scientist Development Award in order to obtain essential skills and mentored research experience for an independent career as a research scientist in the field of pharmacoepidemiology and diabetes. The research proposal details a five-year plan consisting of in-depth training in novel causal inference methods, mentorship by Dr. Morgan Grams, MD, PhD, and Dr. Elizabeth Selvin, PhD, MPH, and pharmacoepidemiologic research in utilization, effectiveness, and safety of second-line therapy in patients with type 2 diabetes. The specific aims of the research agenda are to: 1) Describe the real-world epidemiology of second-line therapy among people with diabetes after metformin monotherapy; 2) Evaluate real-world effectiveness of 5 classes of second-line therapy for hyperglycemia management among similar people with diabetes after metformin monotherapy; and 3) Evaluate real-world risks of adverse events and benefits on long-term clinical outcomes of 5 classes of second- line therapy among similar people with diabetes after metformin monotherapy. Immediate career goals include the mastery of applying target trial emulation and estimating the effect of a dynamic treatment regime with Robin’s g-methods through an academic curriculum integrated with the research plan. Long-term, Dr. Shin aims to lead independent research programs investigating optimal treatment and decision-making to improve health outcomes of patients with type 2 diabetes. Completion of the proposed aims will provide vital information relevant to the approximately thirty million U.S. patients with type 2 diabetes. Type 2 diabetes is associated with high levels of morbidity and mortality. Although consensus exists around first-line therapy, there remains great uncertainty regarding the optimal choice of a second-line therapy, with inconsistent recommendations across guidelines. A better understanding of the risks and benefits of different classes of second-line antidiabetic drugs would greatly help clinical practice in patients with type 2 diabetes.

项目摘要/摘要 Jung-im Shin，医学博士，博士是约翰·霍普金斯（Johns Hopkins）流行病学系的助理科学家 彭博公共卫生学院。她寻求K01指导的研究科学家发展奖 为了获得基本技能并为研究的独立职业提供研究经验 药物epidemiology和糖尿病领域的科学家。研究建议详细介绍了一个五年计划 包括新的因果推理方法中的深入培训，Morgan Grams，MD的Mentalship，MD， 博士学位和伊丽莎白·塞尔文（Elizabeth Selvin）博士，博士，MPH和Pharmacooepidemiologic in Plistization，Esivealive， 2型糖尿病患者的二线治疗的安全性。研究议程的具体目的 为：1）描述糖尿病患者二线治疗的现实世界流行病学之后 二甲双胍单一疗法； 2）评估5种二线治疗的现实世界有效性 二甲双胍单一疗法后类似糖尿病患者的高血糖管理； 3） 评估现实世界中不良事件的风险，并在5类第二类的临床结果上评估 二甲双胍单一疗法后，类似糖尿病患者的线疗法。直接的职业目标包括 应用目标试验仿真并估算动态治疗方案的效果的掌握 罗宾（Robin）通过与研究计划相结合的学术课程的G-Methods。长期，Shin博士 旨在领导独立研究计划调查最佳治疗和决策以改善 2型糖尿病患者的健康结果。拟议目标的完成将提供重要信息 与大约300万美国2型糖尿病患者有关。 2型糖尿病是相关的 具有高水平的发病率和死亡率。尽管在一线疗法周围存在共识，但仍有 关于二线疗法的最佳选择的极大不确定性，建议不一致 跨指南。更好地理解不同类别的二线类别的风险和好处 抗糖尿病药物将极大地帮助2型糖尿病患者的临床实践。

项目成果

Sodium-Glucose Cotransporter 2 Inhibitors, Glucagon-Like Peptide-1 Receptor Agonists, and Dipeptidyl Peptidase-4 Inhibitors, and Risk of Hospitalization.

• DOI: 10.1016/j.amjcard.2021.11.013
• 发表时间: 2022-02-15
• 期刊: The American journal of cardiology
• 作者: Lyu B;Grams ME;Chang A;Inker LA;Coresh J;Shin JI
• 通讯作者: Shin JI

Do Direct Oral Anticoagulants Have Cardiovascular Benefits in CKD? We Need More Evidence.

直接口服抗凝剂对 CKD 患者有心血管益处吗？

• DOI: 10.1053/j.ajkd.2020.03.025
• 发表时间: 2020
• 期刊: American journal of kidney diseases : the official journal of the National Kidney Foundation
• 作者: Shin,Jung-Im;Grams,MorganE
• 通讯作者: Grams,MorganE

Authors' Reply.

作者的回复。

• DOI: 10.1681/asn.2020081189
• 发表时间: 2020
• 期刊: Journal of the American Society of Nephrology : JASN
• 作者: KurellaTamura,Manjula;Pajewski,Nicholas;Weiner,DanielE
• 通讯作者: Weiner,DanielE

Impact of Socioeconomic Status on Mortality and Readmission in Patients With Heart Failure With Reduced Ejection Fraction: The ARIC Study.

• DOI: 10.1161/jaha.121.024057
• 发表时间: 2022-09-20
• 期刊: JOURNAL OF THE AMERICAN HEART ASSOCIATION
• 影响因子: 5.4
• 作者: Mathews, Lena;Ding, Ning;Mok, Yejin;Shin, Jung-Im;Crews, Deidra C.;Rosamond, Wayne D.;Newton, Anna-Kucharska;Chang, Patricia P.;Ndumele, Chiadi E.;Coresh, Josef;Matsushita, Kunihiro
• 通讯作者: Matsushita, Kunihiro

Use of prescription medications with cardiovascular adverse effects among older adults in the United States.

• DOI: 10.1002/pds.5477
• 发表时间: 2022-10
• 期刊: Pharmacoepidemiology and drug safety
• 影响因子: 2.6